In an effort to provide you with timely market feedback from the 58th ASH Annual Meeting held in December 2016, OBR and MDoutlook® are pleased to share results from MDoutlook’s OncoPolls™ conducted last month immediately after the meeting. This report explores the choice between Rituxan® and Gazyva® in the front line setting for follicular lymphoma (FL) and diffuse large B-cell lymphoma (DLBCL) and the use of Rituxan and Revlimid® in the maintenance setting for mantle cell and CLL, respectively.
- Primary research phase involved a survey to verified and validated US hematological and medical oncologists with an identified clinical interest in B-cell lymphomas utilizing targeting parameters within the proprietary MDoutlook global cancer treater panel
- Timing: December 2016. Launched 9 days after close of 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA, December 3-6, 2016
- Fielding to proprietary panel of cancer treaters, targeted by clinical interest
- Data capture via interactive web-based survey instrument, utilizing proven MDoutlook methodology and proprietary technology
- Links to discussed abstracts on the ASH website were provided within the survey
- Reponses at data collection: 100
Institutional Setting by Attendance of Respondents
Use of anti-CD20 mAbs in the Front Line for Different B-cell Lymphomas
Awareness of Abstracts #6 & #470
General Clinical Importance of Different anti-CD20 mAbs in FL & DLBCL
Expected Impact on anti-CD20 Usage in FL & DLBCL
- On a 0 – 5 scale of 0 = no awareness to 5 = very aware, clinicians have only an average / slightly below average awareness of these presentations
- A general higher level of awareness is seen by those who attended ASH (nearly a full rating point higher for each abstract)
- The average level awareness about the FL abstract is somewhat lacking considering it was presented in the Plenary Session
- Clinical impact of these presentations, rated on a 1 – 5 scale of 1 = not at all important to 5 = very important, is seen as being very clinically meaningful
- US oncologists assign a high importance (>4) to the FL presentation (Abstract #6), regardless of meeting attendance
- Abstract #470 (concerning DLBCL) is seen as somewhat less important, especially by those who did not attend the meeting
- Expected impact on anti-CD20 mAb usage in their practice was also measured. A 14-22% absolute growth in usage of Gazyva is predicted in the near future, all at the expense of Rituxan usage. No real changes noted in patients not treated with anti-CD20 antibodies or with other anti-CD20 antibodies (not shown). With greater impact seen with non-attendees, this shows the importance of the information itself, compared to the need to be present at the meeting for changing practices.
Use of Maintenance Strategies for Mantle Cell Lymphoma and CLL
Awareness of Abstracts #145, #229 & #230
General Clinical Importance of Maintenance Strategies for Mantle Cell Lymphoma and CLL
Expected Impact on Maintenance Usage in Mantle Cell Lymphoma and CLL
- On the same 0 – 5 scale, attendees of the ASH meeting have an average level awareness about these maintenance presentations, while awareness by non-attendees is low
- No meaningful differences in awareness among these three abstracts
- Upon providing these abstracts for review, US oncologists recognize the clinical importance of this information and plan on incorporating these maintenance strategies into their clinical practices immediately
- Meeting attendance does not really impact these findings. In fact, non-attendees may be more likely to use these approaches in their practices
Conclusions: Immediate Impact of 2016 ASH Presentations on Clinical Practice for B-cell Lymphomas
- All of these studies highlight the importance of the ASH Annual Meeting to the entire hematologic oncology community – awareness of these presentations are high and can occur quite quickly even for those who did not attend the meeting. Alternative methods to disseminate new clinical information are very important to improving clinical practices and patient outcomes
- The information in these presentations will be integrated into clinical practice in relatively short order, especially since most of these agents are already widely available and in use
For a more detailed analysis report, please click here to download the full report.
Submitted by Dr Robert Stephan, VP, Research and Physician Society, and Dr Jan Heybroek, President MDoutlook.